Merck KGAA pays €20mm up front for exclusive rights to Symphogen’s Sym004; rights returned
Symphogen AS (therapies for autoimmune and infectious diseases and cancer) has granted Merck KGAA exclusive worldwide rights to develop and sell its lead project Sym004, an antibody mixture in Phase I/II trials for advanced KRAS wild-type metastatic colorectal cancer patients, who have previously responded to treatment with standard chemo and a marketed anti-EGFR monoclonal antibody.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com